Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells

International Journal of Cancer

Volumn 89, Issue 2, 2000, Pages 385-392

  Mackensen, Andreas ^a,e   Herbst, Birgit ^a   Chen, Ji Li ^b   Köhler, Gabriele ^a   Noppen, Christoph ^c   Herr, Wolfgang ^d   Spagnoli, Giulio C ^c   Cerundolo, Vincenzo ^b   Lindemann, Albrecht ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CANCER VACCINE; CISPLATIN; DACARBAZINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A1 ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; PROTEIN MELAN A; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINBLASTINE; CD34 ANTIGEN; PEPTIDE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; FEMALE; FEVER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR IMMUNITY; VITILIGO; ADOLESCENT; ANTIGEN PRESENTATION; CYTOTOXICITY; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PILOT STUDY; TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; ANTIGEN PRESENTATION; ANTIGENS, CD34; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MELANOMA; MIDDLE AGED; PEPTIDES; PILOT PROJECTS;

EID: 0034181264     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(20000501)86:3<385::aid-ijc13>3.0.co;2-t     Document Type: Article

References (24)

1. BANCHERRAU, J. and STEINMAN, R.M., Dendritic cells and the control of immunity. Nature (Lond.), 392, 245-252 (1998).
2. BOSSERHOFF, A.-K., KAUFMANN, M., KALUZA, B., BARTKE, I., ZIRNGIBL, H., HEIN, R., STOLZ, W. and BUETTNER, R., Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res., 57, 3149-3153 (1997).
3. DUNBAR, P.R., OGG, G.S., CHEN, J., RUST, N., VAN DER BRUGGEN, P. and CERUNDOLO, V., Direct isolation, phenotyping and cloning of low frequency antigen-specific CTL from peripheral blood. Curr. Biol., 8, 413-416 (1998).
4. + hematopoietic progenitor cells toward distinct dendritic cell subsets of the Birbeck granule and MIIC-positive Langerhans cell and the interdigitating dendritic cell type. Blood, 88, 2541-2548 (1996).
5. + peripheral blood progenitor cell-and monocyte-derived dendritic cells: a comparative analysis. Brit. J. Hematol., 99, 490-499 (1997).
6. - T lymphocytes producing tumor necrosis factor a spots in response to peptide antigens. J. Immunol. Methods, 203, 141-152 (1997).
7. + blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet, 352, 1358 (1998).
8. HSU, F.J., BENIKE, C., FAGNONI, F., LILES, T.M., CZERWINSKI, D., TAIDI, B., ENGLEMAN, E.G. and LEVY, R., Vaccination of patients with lymphoma using autologous antigen-pulsed dendritic cells. Nature (Med.), 2, 52-58 (1996).
9. HU, X., CHAKRABORTY, N.G., SPORN, J.R., KURTZMAN, S.H., ERGIN, M.T. and MUKHERJI, B., Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res., 56, 2479-2483 (1996).
10. IWASAKI, A., TORRES, C.A., OHASHI, P.S., ROBINSON, H.L. and BARBER, B.H., The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol., 159, 11-14 (1997).
11. LEE, P.P., YEE, C., SAVAGE, P.A., FONG, L., BROCKSTEDT, D., WEBER, J.S., JOHNSON, D., SWETTER, S., THOMPSON, J., GREENBERG, P.D., ROEDERER, M. and DAVIS, M., Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature (Med.), 5, 677-685 (1999).
12. + hematopoietic progenitor cells. Cancer Immunol. Immunother., 48, 118-122 (1999).
13. MAYORDOMO, J.I., ZORINA, T., STORKUS, W.J., ZITVOGEL, L., CELLUZZI, C., FALO, L.D., MELIEF, C.J., ILDSTAD, S.T., KAST, W.M., DELEO, A.B. and LOTZE, M.T., Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nature (Med.), 1, 1297-1302 (1995).
14. MORSE, M.A., COLEMAN, R.E., AKABANI, G., NIEHAUS, N., COLEMAN, D. and LYERLY, H.K., Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res., 59, 56-58 (1999).
15. 35-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res., 57, 5534-5541 (1997).
16. MUKHERJI, B., CHAKRABORTY, N.G., YAMASAKI, S., OKINO, T., YAMASE, H., SPORN, J.R., KURTZMAN, S.K., ERGIN, M.T., OZOLS, J., MEEHAN, J. and MAURI, F., Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. nat. Acad. Sci. (Wash.), 92, 8078-8082 (1995).
17. NESTLE, F.O., ALIJAGIC, S., GILLIET, M., SUN, Y., GRABBE, S., DUMMER, R., BURG, G. and SCHADENDORF, D., Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature (Med.), 4, 328-332 (1998).
18. NOPPEN, C. SPAGNOLI, G.C. and SCHAEFER, C., Isolation of multiple mRNAs from few eukaryotic cells: a fast method to obtain templates for RT-PCR. Biotechniques, 21, 394-396 (1996).
19. OGG, G.S., DUNBAR, P.R., ROMERO, P., CHEN, J.L. and CERUNDOLO, V., High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. exp. Med., 188, 1203-1208 (1998).
20. ROMERO, P., DUNBAR, P.R., VALMORI, D., PITTET, M., OGG, G.S., RIMOLDI, D., CHEN, J.-L., LIENARD, D., CEROTTINI, J.-C. and CERUNDOLO, V., Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolylic T lymphocytes. J. exp. Med., 188, 1641-1650 (1998).
21. ROSENBERG, S.A. and 15 OTHERS, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature (Med.), 4, 321-327 (1998a).
22. ROSENBERG, S.A., ZHAI, Y., YANG, J.C., SCHWARTZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., TOPALIAN, S.L., RESTIFO, N.P., SIPP, C.A., EINHORN, J.H., ROBERTS, B. and WHITE, D.E., Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. nat. Cancer Inst., 90, 1894-1900 (1998b).
23. TOES, R.E., VAN DER VOORT, E.I., SCHOENBERGER, S.P., DRIJFHOUT, J.W., VAN BLOOIS, L., STORM, G., KAST, W.M., OFFRINGA, R. and MELIEF, C.J., Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol., 160, 4449-4456 (1998).
24. VAN DEN EYNDE, B.J. and VAN DER BRUGGEN, P., T cell defined tumor antigens. Curr. Opin. Immunol., 9, 684-693 (1997).